MOVAPO apomorphine hydrochloride hemihydrate 20 mg/2mL injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

movapo apomorphine hydrochloride hemihydrate 20 mg/2ml injection ampoule

stada pharmaceuticals australia pty ltd - apomorphine hydrochloride hemihydrate, quantity: 20 mg - injection, solution - excipient ingredients: sodium metabisulfite; water for injections; sodium hydroxide; hydrochloric acid - movapo is indicated to reduce the number and severity of "off" phases in patients with parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with movapo should be undertaken by a specialist unit in a hospital setting. conventional therapy should be continued during "on" phases.

MOVAPO PFS apomorphine hydrochloride hemihydrate 50mg/10mL solution for subcutaneous infusion pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

movapo pfs apomorphine hydrochloride hemihydrate 50mg/10ml solution for subcutaneous infusion pre-filled syringe

stada pharmaceuticals australia pty ltd - apomorphine hydrochloride hemihydrate, quantity: 50 mg - injection, solution - excipient ingredients: sodium metabisulfite; water for injections; hydrochloric acid - movapo pfs is indicated to reduce the number and severity of "off" phases in patients with parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine injection should be undertaken by a specialist unit in a hospital setting. conventional therapy should be continued during "on" phases.

STADA IRBESARTAN HCT 300/25 irbesartan/hydrochlorothiazide 300 mg/25 mg tablet blister Australia - English - Department of Health (Therapeutic Goods Administration)

stada irbesartan hct 300/25 irbesartan/hydrochlorothiazide 300 mg/25 mg tablet blister

medis pharma pty ltd - hydrochlorothiazide, quantity: 25 mg; irbesartan, quantity: 300 mg - tablet - excipient ingredients: colloidal anhydrous silica; hydrogenated castor oil; microcrystalline cellulose; maize starch; magnesium stearate; lactose monohydrate; croscarmellose sodium; povidone - stada irbesartan hct is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

STADA IRBESARTAN HCT 150/12.5 irbesartan/hydrochlorothiazide 150 mg/12.5 mg tablet blister Australia - English - Department of Health (Therapeutic Goods Administration)

stada irbesartan hct 150/12.5 irbesartan/hydrochlorothiazide 150 mg/12.5 mg tablet blister

medis pharma pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 150 mg - tablet - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; povidone; microcrystalline cellulose; magnesium stearate; hydrogenated castor oil; maize starch; lactose monohydrate - stada irbesartan hct is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

STADA IRBESARTAN HCT 300/12.5 irbesartan/hydrochlorothiazide 300 mg/12.5 mg tablet blister Australia - English - Department of Health (Therapeutic Goods Administration)

stada irbesartan hct 300/12.5 irbesartan/hydrochlorothiazide 300 mg/12.5 mg tablet blister

medis pharma pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 300 mg - tablet - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; povidone; hydrogenated castor oil; maize starch; magnesium stearate; lactose monohydrate; croscarmellose sodium - stada irbesartan hct is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

STADA OLANZAPINE OD Australia - English - Department of Health (Therapeutic Goods Administration)

stada olanzapine od

generic health pty ltd - olanzapine -

STADA Olanzapine Australia - English - Department of Health (Therapeutic Goods Administration)

stada olanzapine

generic health pty ltd - olanzapine benzoate -

CYSTADANE betaine 1g/g oral powder bottle Australia - English - Department of Health (Therapeutic Goods Administration)

cystadane betaine 1g/g oral powder bottle

recordati rare diseases australia pty ltd - betaine, quantity: 1 g/g - powder, oral - excipient ingredients: - as an adjunct in the treatment of homocystinuria.

CANDESARTAN HCTZ AGH 32/25 candesartan cilexetil 32 mg & hydrochlorothiazide 25 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

candesartan hctz agh 32/25 candesartan cilexetil 32 mg & hydrochlorothiazide 25 mg tablet blister pack

alembic pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 25 mg; candesartan cilexetil, quantity: 32 mg - tablet, uncoated - excipient ingredients: carmellose calcium; maize starch; lactose monohydrate; magnesium stearate; macrogol 8000; hyprolose; iron oxide red - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.

CANDESARTAN HCTZ AGH 32/12.5 candesartan cilexetil 32 mg & hydrochlorothiazide 12.5 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

candesartan hctz agh 32/12.5 candesartan cilexetil 32 mg & hydrochlorothiazide 12.5 mg tablet blister pack

alembic pharmaceuticals australia pty ltd - candesartan cilexetil, quantity: 32 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; hyprolose; macrogol 8000; maize starch; magnesium stearate; carmellose calcium; colour - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.